TGTX Q4 2019 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

-$169M-444781.6% margin

Operating Income

-$38M-99894.7% margin

Net Income

-$40M-104134.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$163M

Total Liabilities

$124M

Stockholders' Equity

$39M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	-$169M	$38,000	-444881.6%
Operating Income	-$38M	-$54M	+29.9%
Net Income	-$40M	-$54M	+26.5%